Inovio Pharmaceuticals Inc (INO)

[Ubertino]

Inovio Launches Zika Vaccine Trial in Midst of Puerto Rico Epidemic to Explore Early Signals of Vaccine Efficacy

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Intraday Stock Chart
Today : Monday 29 August 2016

Click Here for more Inovio Pharmaceuticals, Inc. Charts.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.
Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting. Inovio and its collaborators are moving ahead with this second Zika vaccine clinical trial to evaluate safety, immune responses, and possible signals of vaccine efficacy. If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States.”